Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Aptose Biosciences Inc. (T.APS) had Normalized Pre-Tax Income of -35.60M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-35.60M |
|
-- |
|
-- |
|
-- |
|
-34.56M |
|
-- |
|
-35.60M |
|
|
Normalized Pre-Tax Income |
-35.60M |
-35.60M |
|
-35.60M |
|
-35.60M |
|
-35.60M |
|
-34.56M |
|
-34.52M |
|
2.45M |
|
2.45M |
|
-14.55 |
|
-14.55 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
13.99M |
|
-- |
|
-- |
|
-- |
|
51.97M |
|
-37.97M |
|
-37.97M |
|
-37.97M |
|
2.55M |
|
| Cash Flow Statement Financials | |
-30.74M |
|
-- |
|
27.09M |
|
9.37M |
|
5.72M |
|
-3.65M |
|
0.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.69 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.74M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
93.75% |
|
93.75% |
|
-254.37% |
|
93.75% |
|
-14.88 |
|
-12.56 |
|
-12.56 |
|